Lv1
56 积分 2023-11-13 加入
International Cost‐Effectiveness Analysis of Nivolumab Versus Brentuximab Vedotin for Patients With Advanced‐Stage Classic Hodgkin's Lymphoma
1天前
已完结
A Comprehensive Genetic Study of Classical Hodgkin Lymphoma Using Circulating Tumor DNA
28天前
已关闭
Beyond CD30: Dual‐Targeting of Malignant and Regulatory T Cells by Brentuximab Vedotin Remodels the Lymphoma Microenvironment and Overcomes Resistance via BCL2 Inhibition in Mycosis Fungoides
1个月前
已完结
Beyond CD30: Dual‐Targeting of Malignant and Regulatory T Cells by Brentuximab Vedotin Remodels the Lymphoma Microenvironment and Overcomes Resistance via BCL2 Inhibition in Mycosis Fungoides
1个月前
已完结
[18F]FDG PET/CT for outcome prediction in diffuse large B-cell lymphoma treated with polatuzumab vedotin-containing regimens
1个月前
已完结
Real-World Outcomes in Myeloma Patients With t (11;14): A Matched Comparison Using the Canadian Myeloma Research Group National Clinical Database
1个月前
已关闭
Clinical implications of CSF-ctDNA positivity in newly diagnosed diffuse large B cell lymphoma
1个月前
已完结
Circulating Tumor DNA Sequencing for Biologic Classification and Individualized Risk Stratification in Patients With Hodgkin Lymphoma
1个月前
已完结
Patterns of Distress and Symptom Burden Among Female Adolescent and Young Adult Survivors of Breast and Gynecological Cancers
1个月前
已完结
A New Interpretation of the Weighted Kappa Coefficients
2个月前
已完结
皖公网安备34019202002308
